Weight-loss drug for treating early endometrial cancer or atypical hyperplasia
Treatments studied
Part of Cancer, Women’s health & pregnancy clinical trials.
This study tests whether a weight-loss medication (tirzepatide) can help shrink early-stage, low-grade endometrial cancer or atypical hyperplasia while you keep your uterus for future pregnancy. It is designed for women who are overweight and wish to preserve their fertility.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Your BMI (a measure of weight relative to height) is 27 or higher.
- You have a low-grade (grade 1 or 2) endometrioid endometrial cancer or atypical hyperplasia, which means the cells are not very aggressive.
- You want to keep the possibility of having children in the future.
- You have not used any weight-loss medication in the last 2 months and have not had weight-loss surgery before.
- You are generally in good health (able to perform daily activities without trouble).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This study tests whether a diabetes medication called tirzepatide, combined with a hormone-releasing device, can help shrink or stop early-stage endometrial cancer (cancer of the uterine lining) in patients who are overweight and either cannot have surgery right away or prefer to delay it. The goal is to see if this approach can be an alternative to immediate surgery.
This trial tests if the weight-loss drug tirzepatide can help people with obesity-related endometrial cancer before their hysterectomy. It may improve surgical outcomes and overall health.
This trial tests if tirzepatide, a drug that helps with weight loss, can improve outcomes for women with obesity and certain early-stage endometrial conditions before a planned hysterectomy.
This study tests if adding a weight loss medication (tirzepatide or semaglutide) during chemotherapy helps people with early-stage endometrial cancer who are overweight or have diabetes. It aims to see if weight loss can improve treatment outcomes.
This study looks at whether a hormone-releasing IUD (LNG-IUS) can treat early-stage endometrial cancer or very early abnormal cell growth while helping you keep the option for future pregnancy. It aims to see how well the treatment works and how it affects fertility-related outcomes.
This study tests a weight-loss drug (tirzepatide) combined with a hormone-releasing IUD to treat certain early-stage uterine conditions without surgery. It may help women who are overweight or obese and want to avoid hysterectomy.
Hear when a new Endometrial Cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.